GALNT7: A Potential Drug Target and Biomarker for Disease (G101930370)

Target Name: GALNT7-DT

NCBI ID: G101930370

GALNT7-DT

Other Name(s): GALNT7 divergent transcript, transcript variant 1 | GALNT7 divergent transcript

GALNT7: A Potential Drug Target and Biomarker for Disease

GALNT7-DT, also known as GALNT7-Divergent Transcript or GALNT7, is a gene that encodes for a protein known as GALNT7. GALNT7 is a member of the GALNT family of proteins, which are involved in the processing and transport of genetic information in the cell. GALNT7 is specifically known for its role in the regulation of gene expression and has been implicated in a number of cellular processes, including cell growth, differentiation, and metabolism.

Recent studies have suggested that GALNT7 may be a potential drug target or biomarker for a number of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. This is because GALNT7 has been shown to play a role in the regulation of cellular processes that are often disrupted in these conditions, such as the rapid cell division that occurs in cancer cells, the misregulation of gene expression that occurs in neurodegenerative diseases, and the dysregulation of metabolism that can occur in psychiatric disorders.

One of the key reasons for the potential drug-targeting potential of GALNT7 is its involvement in the regulation of cell division. GALNT7 has been shown to play a role in the regulation of mitosis, the process by which a cell divides, and it is thought to do so by controlling the movement of chromosomes during the cell division process. In addition, GALNT7 has been shown to interact with the protein p21, which is a key regulator of cell division and is often activated in response to changes in the cellular environment.

Another potential drug-targeting aspect of GALNT7 is its role in the regulation of gene expression. GALNT7 has been shown to play a role in the regulation of gene expression by interacting with the RNA polymerase II complex, a protein that is responsible for transcribing DNA into RNA. This interaction between GALNT7 and RNA polymerase II suggests that GALNT7 may be a useful target for drugs that are designed to disrupt the activity of this complex and inhibit gene expression.

In addition to its potential role in drug targeting, GALNT7 has also been shown to be a potential biomarker for a number of diseases. For example, GALNT7 has been shown to be overexpressed in a variety of cancer tissues and has been used as a biomarker for the diagnosis and prognosis of cancer. In addition, GALNT7 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and has been used as a potential biomarker for these conditions.

Overall, GALNT7 is a gene that has a number of potential targets for drugs and biomarkers. Its involvement in the regulation of cell division, gene expression, and cellular processes that are often disrupted in disease makes it a promising target for a variety of therapeutic approaches. Further research is needed to fully understand the role of GALNT7 in disease and to develop effective treatments.

Protein Name: GALNT7 Divergent Transcript

The "GALNT7-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT7-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets